These considerations also bear on access problems for other essential and lifesaving biological drugs. In parallel, WHO should establish an evaluation scheme of biological drugs to promote product availability and affordability. ![]() In particular, WHO should re-examine its 2009 ‘Guidelines on Evaluation of Similar Biotherapeutic Products’ in light of recent international debates about clinical comparative exercises and of accumulated regulatory experience on biosimilars. We have indentified six pegylated interferon alphas, which could be evaluated to expand the pool of quality assured products.Ĭonclusion: WHO added pegylated interferon alpha to its Essential Medicines List released in July 2013, but other steps – and more progressive WHO guidance – are needed to ensure more immediate treatment options for patients in developing countries. By allowing generics competition Egypt lowered the price of the innovator products to around US$40 per week, while Iran used technology transfer to establish local production and ensure availability within its health system. So far, only a few countries have carved out exceptions to this high price. Results: The price of the innovator products ranges from US$200 to US$375 per vial, meaning that a full (48 weeks) treatment course costs US$10,000–US$20,000 per patient in the surveyed countries. In parallel, we conducted a review of the biosimilars guidance by World Health Organization (WHO) and by selected national drug regulatory agencies. Methods: We compiled information on marketed biosimilars and alternative pegylated interferon alpha products and price information on the innovator products in several developing countries. However, the limited availability and high cost of this medicine is a major barrier to expanding access to treatment in developing countries. At present, the recommended treatment is pegylated interferon alpha (in combination with ribavirin). ![]() Introduction: The current pipeline of promising oral hepatitis C drugs could lead to a revolution in treatment for this disease in both developed and developing countries. Author byline as per print journal: Barbara Milan, Sara Gaspani
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |